Search

Search Results

• TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi, Dr. Galli, Prof. Patrizia Chiusolo

  e2025039

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.039

  1926

  PDF: 1355

  HTML: 246

• CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,

  Ugo Testa, Giuseppe Leone, Elvira Pelosi, Dr. Germana Castelli, Prof. Hohaus

  e2023066

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.066

  3561

  PDF: 1369

  HTML: 168

• CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment

  Ugo Testa, Elvira Pelosi, Dr. Germana Castelli

  e2024077

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.077

  1648

  PDF: 793

  HTML: 137

• Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA

  Michele Puppi, Ilaria Sacchetti, Katia Mancuso, Paola Tacchetti, Lucia Pantani, ilaria Rizzello, Miriam Iezza, Marco Talarico, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Silvia Armuzzi, Barbara Taurisano, Ilaria Vigliotta, Elena Zamagni

  e2025045

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.045

  1447

  PDF: 1132

  HTML: 171

• CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL

  Ugo Testa, Prof. Sica, Dr. Pelosi, Dr. Germana Castelli, Prof. Leone

  e2024010

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.010

  3748

  PDF: 3077

  HTML: 182

• Guest Edtor: Pellegrino Musto NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES

  Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani

  e2025027

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.027

  1293

  PDF: 1162

  HTML: 244

• THE GROWING ROLE OF THE BH3 MIMETIC DRUG VENETOCLAX IN THE THERAPY OF ACUTE MYELOID LEUKEMIA

  Elvira Pelosi, Dr. Germana Castelli, Ugo Testa

  e2022080

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.080

  1366

  PDF: 1088

  HTML: 244

• CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES

  Ugo Testa, Prof. Patrizia Chiusolo, Dr. Elvira Pelosi, Dr. Germana Castelli, Giuseppe Leone

  e2024031

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.031

  2077

  PDF: 1929

  HTML: 143

• CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL

  Ugo Testa, Dr. Elvira Pelosi, Dr. Germana Castelli, Dr. Alberto Fresa, Prof. Luca Laurenti

  e2024045

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.045

  3388

  PDF: 1459

  HTML: 65

• CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma

  Ugo Testa, Francesco D'Alò, Elvira Pelosi, Germana Castelli, Giuseppe Leone

  e2024012

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.012

  2079

  PDF: 1740

  HTML: 119

• SARS-CoV-2 INFECTED PATIENTS: FROM A HEMATOLOGIST PERSPECTIVE COVID-19 and Hematology

  Firas Kreidieh, Sally Temraz

  e2020078

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.078

  988

  PDF: 931

  HTML: 302

• Guest Editor: Pellegrino Musto AN UPDATE OF THE APPROPRIATE SEQUENCING FOR SALVAGE THERAPIES IN MULTIPLE MYELOMA

  Gregorio Barila', Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello

  e2025043

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.043

  1080

  PDF: 891

  HTML: 124

• BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL

  Ugo Testa, Elvira Pelosi, Germana Castelli, Patrizia Chiusolo

  e2024070

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.070

  1541

  PDF: 1039

  HTML: 99

• Guest Editor: Pellegrino Musto HOW FIRST LINE THERAPY IS CHANGING IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

  Yasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda

  e2025026

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.026

  1770

  PDF: 1527

  HTML: 115

• NOVEL DRUGS IN FOLLICULAR LYMPHOMA

  Giuseppe Rossi, Antonella Anastasia

  e2016061

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.061

  4242

  PDF: 1449

  HTML: 1531

  Untitled: 210

• CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY/UNFIT PATIENTS AFFECTED BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SINGLE-CENTRE EXPERIENCE.

  Luca Laurenti, Barbara Vannata, Idanna Innocenti, Francesco Autore, Francesco Santini, Nicola Piccirillo, Tommaso Za, Silvia Bellesi, Sara Marietti, Simona Sica, Dimitar G. Efremov, Giuseppe Leone

  e2013031

  2013-05-01

  https://doi.org/10.4084/mjhid.2013.031

  3040

  PDF: 858

  HTML: 1523

  Fig.1 CHL-R paper: 191

  Fig 2 CHL-R paper: 219

• UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

  José Luis Piñana, Estela Giménez, Lourdes Vázquez, María Ángeles Marcos, Manuel Guerreiro, Rafael Duarte, Ariadna Pérez, Carlos de Miguel, Ildefonso Espigado, Marta González-Vicent, María Suarez-Lledó, Irene García-Cadenas, Rodrigo Martino, Angel Cedillo, Monserrat Rovira, Rafael de la Cámara, David Navarro, Carlos Solano

  e2024065

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.065

  3747

  Suppl. Files: 1047

  PDF: 1020

  Html: 107

• INFECTIOUS RISKS AND COMPLICATIONS IN ADULT LEUKEMIC PATIENTS RECEIVING BLINATUMOMAB

  Wonhee So, Shuchi Pandya, Rod Quilitz, John Greene

  e2018029

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.029

  2714

  PDF: 996

  HTML: 290

• APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Tadeusz Robak

  e2010011

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.011

  1620

  PDF: 623

  HTML: 2414

• FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-T Cells

  Eugenio Galli, Filippo Frioni, Tanja Malara, Enrico Attardi, Silvia Bellesi, Stefan Hohaus, Simona Sica, Federica Sorà, Patrizia Chiusolo

  e2024029

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.029

  901

  PDF: 1180

  HTML: 89

• EFFICACY AND SAFETY OF CLADRIBINE: SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN HAIRY CELL LEUKEMIA PATIENTS

  Ola Khorshid, Safaa M. Ramadan

  e2015058

  2015-10-16

  https://doi.org/10.4084/mjhid.2015.058

  1947

  PDF: 1029

  HTML: 1183

• TDT Positive High-Grade Lymphoma with Myc, BCL2 And BCL6 Rearrangements: a Review of Diagnosis and Treatment TDT POSITIVE HIGH-GRADE LYMPHOMA WITH MYC, BCL2 AND BCL6 REARRANGEMENTS.

  Aditi Singh, MD, Ishaq Asghar, MD, Laura Kohler, DO, Hosam Hakim, MD, Daniel Snower, MD, Daniel Lebovic, MD

  e2022018

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.018

  1590

  PDF: 706

  HTML: 457

• EFFICACY AND SAFETY OF THALIDOMIDE IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA: A SYSTEMATIC REVIEW, META-ANALYSIS AND GRADE EVALUATION

  Jialian Li, Ping Ji, Qinyue Zhong, Lin Dong, Hai Yi, Baiyu Chen, Xu Zhang, Tingting Duan

  e2026033

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.033

  0

  PDF: 0

  Suppl. Files: 0

  HTML: 0

• POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.

  Sinem Başak Tan Öksüz, Güldane Cengiz Seval, Klara Dalva, Selami Koçak Toprak

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.028

  562

  PDF: 276

  Suppl. Files: 102

  HTML: 96

• AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS

  Giuseppe Visani, Paola Picardi, Patrizia Tosi, Alessandro Isidori

  e2012075

  2012-11-07

  https://doi.org/10.4084/mjhid.2012.075

  2445

  PDF: 841

  HTML: 2109

• Impressive continuous complete response after mogamulizumab in a heavily pre-treated Sézary syndrome patient

  Pier Luigi Zinzani, Ginevra Lolli, Beatrice Casadei, Lisa Argnani, Laura Nanni, Michele Cavo

  e2020040

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.040

  974

  PDF: 642

  HTML: 192

• Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

  Daniele Derudas

  e2025025

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.025

  1444

  PDF: 1261

  HTML: 105

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  1984

  PDF: 1600

  HTML: 345

• Acquired CD20 Loss as a Mechanism of Resistance to Mosunetuzumab in Relapsed Follicular Lymphoma

  Martina Canichella, Stefano Fratoni, Carla Mazzone, alice di rocco, elisabetta abruzzese

  e2026014

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.014

  650

  PDF: 592

  Html: 118

• UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

  Patrizia Tosi, Manuela Imola, Mianulli Anna Maria, Simona Tomassetti, Anna Merli, Annalia Molinari, Serena Mangianti, Marina Ratta, Alessandro Isidori, Giuseppe Visani

  e2012069

  2012-11-05

  https://doi.org/10.4084/mjhid.2012.069

  2420

  PDF: 678

  HTML: 1507

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1605

  PDF: 1602

  HTML: 750

• Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure Memory Cell Population Of Natural Killer Cells in COVID-19 and Cytomegalovirus Exposure

  SUPARNO CHAKRABARTI

  e2020047

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.047

  1084

  PDF: 875

  HTML: 280

• OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT

  Ulrike Bacher, Stefanie von Matt, Yara Banz, Behrouz Mansouri, Urban Novak, Thomas Pabst

  e2023025

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.025

  1228

  HTML: 282

  PDF: 899

  Suppl. Files: 431

• PLASMA CELL LEUKEMIA UPDATE ON IMMUNOPHENOTYPE, MOLECULAR CHARACTERISTICS, AND THERAPY. The second part of plasma cell neoplasms with spreading in the blood and tissues Plasma Cell Leukemia

  Giuseppe G.M. Leone, Ugo Testa

  e2025080

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.080

  867

  PDF: 297

  Html: 68

• NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

  Dimitar Efremov, Adrian Wiestner, Luca Laurenti

  e2012067

  2012-10-09

  https://doi.org/10.4084/mjhid.2012.067

  2434

  PDF: 817

  HTML: 8788

  Efremov 1: 205

  Efremov 2: 165

• Efficacy and safety of teclistamab followed by autologous stem cells transplant in functional high-risk and triple class refractory multiple myeloma

  Vincenzo Sammartano, Sara Ciofini, Beatrice Esposito Vangone, Chiara Carrara, Monica Bocchia, Alessandro Gozzetti

  e2025051

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.051

  675

  PDF: 535

  HTML: 19

• Managment of Relapsed/Refractory ALL With Inotuzumab During COVID-19. A Casr Report

  Martina Di Palma, Elio Gentilini, Chiara Masucci, Alessandra Micozzi, Ombretta Turriziani, Antonino Mulè, Robin Foà, Maurizio Martelli, Gabriella D'Ettorre, Saveria Capria, Sabina Chiaretti

  e2022043

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.043

  1262

  PDF: 540

  HTML: 204

• EBV IN HODGKIN LYMPHOMA

  Giuseppina Massini, Doerte Siemer, Stefan Hohaus

  e2009013

  https://doi.org/10.4084/mjhid.2009.013

  1595

  PDF: 569

  HTML: 13912